Back to News
Market Impact: 0.28

MetLife: Time To Go Long The Common Shares And 6.35% Yielding Preferreds

Corporate EarningsCompany FundamentalsCapital Returns (Dividends / Buybacks)Interest Rates & YieldsCredit & Bond Markets

MetLife is described as delivering robust adjusted income, supporting a bullish view on both common shares and preferreds. The company’s preferred dividend payout ratio remains low, and $24.5B of common equity provides strong downside protection for preferred holders. Series A floating-rate preferreds yield 5.45%-5.5%, while fixed-rate Series F offers a higher current yield.

Analysis

The key takeaway is not just that MET is generating enough earnings to support its equity and preferred stack, but that the capital structure is giving investors a clean read-through on balance-sheet resilience. When common equity is this large relative to preferred obligations, the preferreds behave less like a distressed credit instrument and more like a quasi-rate product with an equity cushion; that tends to compress downside volatility even if common-stock sentiment weakens. The market may be underappreciating that the preferreds should re-rate not only on yield, but on perceived permanence of the dividend stream. Second-order beneficiaries are income allocators who need duration but still want issuer-specific protection: MET’s fixed-rate preferreds can attract switching flows from lower-quality financial preferreds if credit spreads widen. If short-term rates stay elevated or move higher, the floating-rate series should outperform on price stability, but the fixed-rate series can still win on total return if long-end yields fall or if investors begin to pay up for spread compression. The subtle dynamic is that the preferred complex could become a relative-value trade against Treasuries and bank preferreds rather than a pure standalone call on MetLife fundamentals. The main risk is that the bullish thesis on the common and preferreds diverges if capital returns accelerate for common holders while management becomes more selective with preferred treatment in a stress scenario. That said, the reversal catalyst is likely to be macro, not idiosyncratic: a meaningful drop in rates would reduce the appeal of floating-rate paper, while a spread shock would hit all financial preferreds and force a reassessment of hybrid capital pricing. Over the next 1-3 months, the name is likely to remain supported; over 6-12 months, the key variable is whether the market starts treating MET as a high-quality capital-return compounder rather than just an insurance balance-sheet story. Consensus is likely too focused on current yield and too little on embedded protection. The preferreds appear underpriced versus the common equity buffer, but the better relative-value expression may be owning MET preferreds versus lower-balance-sheet-quality financial preferreds where dividend coverage is more rate-sensitive and less overcollateralized. For the common, the bullish case is more muted than for the preferreds: upside likely depends on a rerating of capital return credibility rather than multiple expansion alone.